Posted by Michael Wonder on 26 Sep 2022
Ezharmia approved in Japan as first dual EZH1 and EZH2 inhibitor therapy for patients with adult T-Cell leukaemia/lymphoma
26 September 2022 - Approval based on pivotal Phase 2 trial where Ezharmia demonstrated an objective response rate of 48% in previously treated patients.
Daiichi Sankyo today announced that the Japan MHLW has approved Ezharmia (valemetostat tosylate), a first-in-class dual inhibitor of EZH1 and EZH2, for the treatment of patients with relapsed or refractory adult T-cell leukaemia/lymphoma.
